Follow on Google News News By Tag * Kinase Therapeutics * Pipeline Assessment * Commercial Prospects * Market Research Reports * Market Research Report * More Tags... Industry News Country(s) Industry News
Follow on Google News | Kinase Therapeutics: Pipeline Assessment and Commercial Prospects Now Available on ReportsandReportsThe number of kinase inhibitors entering clinical development has increased significantly in recent years. In addition to major pharmaceutical and biotech companies, an increasing number of emerging companies are focusing on their development.
By: ReportsandReports The number of kinase inhibitors entering clinical development has increased significantly in recent years. In addition to major pharmaceutical and biotech companies, an increasing number of emerging companies are focusing on their development. By 2020, small-molecule kinase inhibitors could generate annual revenues > $25 billion. This report assesses: - R&D considerations specific to targeting kinases - Current kinase inhibitor pipelines - Commercial successes to date - Near- and longer-term market outlook - Corporate activities of firms involved with kinases Kinases are now firmly established as a major class of drug targets. It was previously thought that kinases would be intractable drug targets due to the presumed need to compete with ATP and the assumption that sufficient selectivity would be unattainable. However, considerable progress has been made in understanding kinases and their function, and the past few years have seen a number of kinase inhibitors reach the market. Imatinib (Novartis’ Gleevec) is currently the most commercially successful, with sales reaching $3.7 billion in 2008. Erlotinib (OSI/Roche’s Tarceva) generated revenues of $1.1 billion the same year. In recent years, there has been an explosion in the number of kinase inhibitors entering the clinic, and many more are in preclinical development. Kinase Therapeutics: TABLE OF CONTENTS CHAPTER 1: KINASES CHAPTER 2: INDICATIONS CHAPTER 3: R&D CONSIDERATIONS CHAPTER 4: CURRENT COMMERCIAL SUCCESSES CHAPTER 5: CURRENT KINASE INHIBITOR PIPELINES CHAPTER 6: CORPORATE ACTIVITIES CHAPTER 7: MARKET OUTLOOK CHAPTER 8: EXPERT INTERVIEWS Browse the complete Report on: http://www.reportsandreports.com/ Related Reports: http://www.reportsandreports.com/ http://www.reportsandreports.com/ http://www.reportsandreports.com/ About Us ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers. Contact: Ms. Sunita 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-989-8004 Website: http://www.reportsandreports.com/ Blog: http://reportsnreports.wordpress.com/ End
|
| |||||||||||||||||||||||||||||||||||||||||||
